Bank of America’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-554,943
| Closed | -$9.98M | – | 7419 |
|
|
2020
Q2 | $9.98M | Sell |
554,943
-112,535
| -17% | -$1.57M | ﹤0.01% | 2214 |
|
|
2020
Q1 | $4.76M | Buy |
667,478
+76,935
| +13% | +$960K | ﹤0.01% | 2709 |
|
|
2019
Q4 | $14.1M | Sell |
590,543
-9,121
| -2% | -$252K | ﹤0.01% | 2216 |
|
|
2019
Q3 | $16.1M | Sell |
599,664
-14,411
| -2% | -$405K | ﹤0.01% | 2044 |
|
|
2019
Q2 | $16.7M | Buy |
614,075
+14,357
| +2% | +$450K | ﹤0.01% | 2034 |
|
|
2019
Q1 | $20.8M | Buy |
599,718
+347,458
| +138% | +$10M | ﹤0.01% | 1788 |
|
|
2018
Q4 | $4.92M | Buy |
252,260
+70,196
| +39% | +$1.44M | ﹤0.01% | 3005 |
|
|
2018
Q3 | $4.85M | Sell |
182,064
-133,146
| -42% | -$4.35M | ﹤0.01% | 3205 |
|
|
2018
Q2 | $11.9M | Buy |
315,210
+99,052
| +46% | +$3.79M | ﹤0.01% | 2289 |
|
|
2018
Q1 | $7.06M | Buy |
216,158
+20,008
| +10% | +$878K | ﹤0.01% | 2747 |
|
|
2017
Q4 | $9.55M | Sell |
196,150
-21,516
| -10% | -$1.09M | ﹤0.01% | 2492 |
|
|
2017
Q3 | $11.8M | Buy |
217,666
+42,216
| +24% | +$2.48M | ﹤0.01% | 2353 |
|
|
2017
Q2 | $9.86M | Sell |
175,450
-5,515
| -3% | -$221K | ﹤0.01% | 2385 |
|
|
2017
Q1 | $7.09M | Buy |
180,965
+16,306
| +10% | +$519K | ﹤0.01% | 2717 |
|
|
2016
Q4 | $3.69M | Buy |
164,659
+6,897
| +4% | +$135K | ﹤0.01% | 3220 |
|
|
2016
Q3 | $3.58M | Buy |
157,762
+3,840
| +2% | +$90.1K | ﹤0.01% | 3140 |
|
|
2016
Q2 | $3.63M | Sell |
153,922
-2,750
| -2% | -$67.9K | ﹤0.01% | 3085 |
|
|
2016
Q1 | $3.2M | Sell |
156,672
-45,395
| -22% | -$1.44M | ﹤0.01% | 3172 |
|
|
2015
Q4 | $10.4M | Buy |
202,067
+14,385
| +8% | +$697K | ﹤0.01% | 2226 |
|
|
2015
Q3 | $8M | Buy |
187,682
+83,412
| +80% | +$4.02M | ﹤0.01% | 2419 |
|
|
2015
Q2 | $4.75M | Buy |
104,270
+62,297
| +148% | +$2.51M | ﹤0.01% | 2624 |
|
|
2015
Q1 | $1.59M | Buy |
41,973
+36,460
| +661% | +$1.25M | ﹤0.01% | 3430 |
|
|
2014
Q4 | $156K | Buy |
5,513
+2,024
| +58% | +$56.3K | ﹤0.01% | 5563 |
|
|
2014
Q3 | $88K | Buy |
3,489
+3,437
| +6,610% | +$90.5K | ﹤0.01% | 6110 |
|
|
2014
Q2 | $2K | Sell |
52
-1,973
| -97% | -$47.8K | ﹤0.01% | 7854 |
|
|
2014
Q1 | $52K | Sell |
2,025
-1,567
| -44% | -$41.8K | ﹤0.01% | 6397 |
|
|
2013
Q4 | $92K | Buy |
3,592
+2,322
| +183% | +$56.4K | ﹤0.01% | 6188 |
|
|
2013
Q3 | $34K | Sell |
1,270
-14,095
| -92% | -$335K | ﹤0.01% | 6644 |
|
|
2013
Q2 | $377K | Buy |
+15,365
| New | +$305K | ﹤0.01% | 5016 |
|
Bank of America's PTLA Position: Q3 2020 in Review
Bank of America sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 554,943 shares — an estimated $9.98M sold.
Bank of America first reported a position in PTLA in Q2 2013 and held it in 29 quarters. The position peaked at $20.8M in Q1 2019. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Bank of America reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Bank of America sold 554,943 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $9.98M.
- Bank of America first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
- Bank of America's Portola Pharmaceuticals, Inc. position peaked at $20.8M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Bank of America's 13F filing for Q3 2020, filed 13 Nov 2020.